Genmab Analyst Price Targets - Benzinga

Genmab AS

GMABNASDAQ

Trade with Public

Trade with Public

$34.75

0.200.58%

Ult. Agg.: Oct 2, 4:49 PM

$34.81

0.260.75%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Genmab Analyst Price Targets - Benzinga

Genmab Analyst Price Targets

Wall Street analyst price targets and consensus rating for Genmab (GMAB).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$39Upside to Avg. PT+12.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 14, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Aug 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$40→$42
Jul 22, 2026	TD Cowen	Yaron Werber	Upgrade	Hold→Buy	$32→$43
Jul 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$38→$40
Jun 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$38
Apr 30, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$40→$38
Mar 27, 2026	Wolfe Research	Kalpit Patel	Initiate	Outperform	$32
Mar 2, 2026	Wells Fargo	Eva Fortea Verdejo	Initiate	Overweight	$40
Feb 23, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$40
Feb 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$39→$40
Feb 17, 2026	Jefferies	Benjamin Jackson	Reinstates	Buy	$42
Feb 16, 2026	Morgan Stanley	Judah Frommer	Reinstates	Equal-Weight	$34
Jan 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$39
Jan 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$41→$39
Nov 10, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$41
Nov 7, 2025	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$49→$48
Oct 15, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Oct 2, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$36→$40
Sep 24, 2025	Guggenheim	Michael Schmitz	Upgrade	Neutral→Buy	$43
Sep 23, 2025	Guggenheim	Michael Schmidt	Upgrade	Neutral→Buy	$43

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Genmab, Raises Price Target to $42

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.

Benzinga Newsdesk

PRO
TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43

TD Cowen analyst Yaron Werber upgrades Genmab (NASDAQ:GMAB) from Hold to Buy and raises the price target from $32 to $43.

Benzinga Newsdesk

Amazon To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westlake, Genmab, Levi Strauss, Generac, General Mills, and Amazon.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $38 to $40.

Benzinga Newsdesk

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.

Vandana Singh